Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novartis AG (NVS) vs S&P500 ETF (SPY) Price & Performance

Novartis AGTrade
S&P500 ETFTrade

Price performance (Past 24H)

Key statistics

Novartis AG vs S&P500 ETF — how do they compare? Novartis AG trades at $153.53 (market cap $298.18B), while S&P500 ETF trades at $771.63. The key difference: Novartis AG pays a 3.02% dividend while S&P500 ETF pays none, and S&P500 ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.

NVSSPY
Market Cap
$298.18B
Sector
Health
52-Week High
$168.62$773.22
52-Week Low
$119.31$631.99
Enterprise Value
$339.50B
Dividend Yield
3.02%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novartis AG

Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.

The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.

S&P500 ETF

SPY, the SPDR S&P 500 ETF, trades at $773.22, up 0.6% with a bullish technical signal from moving averages. The ETF shows strong institutional interest and benefits from robust S&P 500 earnings growth, though RSI indicates short-term overbought conditions. A dividend of $1.90 is scheduled for July 2026, adding income appeal.

Outlook remains positive with JPMorgan raising its S&P 500 target to 8,000, driven by AI-driven earnings. Risks include high valuations and potential pullbacks from overbought levels. Investors should weigh long-term growth against near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS

About S&P500 ETF

The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

Read more on SPY